Securing the oligonucleotide supply chain: addressing raw material risks, environmental pressures, and geopolitical factors

“There are still lessons to be learnt for all of us, but we need to keep reinforcing that we are acting scientifically and ethically so that regulators feel more reassured even if they are not fully aware of the whole context.”

The rapid growth of the oligonucleotide therapeutics field has highlighted how vulnerable the supporting supply chain can be. As the demand increases, manufacturers must face constraints in raw materials, increasing environmental pressures, and a shifting geopolitical landscape. Companies must adopt strategic measures to ensure an adequate supply of raw materials.

Nucleic Acid Insights brought together a panel of experts to discuss the key challenges and emerging solutions in this space: Louis Diorazio (Senior Principal Scientist, New Modalities, AstraZeneca), Dennis Rhodes (Associate Director, Analytical Development and Quality Control, Ionis Pharmaceuticals) and Subhadeep (Shubh) Roy (Independent Consultant). The discussion covers how the industry can build supply chain resilience, mitigate risk, and create sustainable supply networks for oligonucleotide therapeutics.

Please enter your email to access content Read now